Amid all the new high-tech therapies on display at the ESMO cancer conference ... compared to CRT alone. After five years of follow-up, 80% of women who received the more intensive treatment ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

Jakafi ® (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

Regulatory News: Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take ...

And now, 24 years later, the walls of the first two stores are finally going up. Construction has started on Sprouts and Target. Low gray walls are up at what will be Sprouts, closest to Clovis ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...